Atrial fibrillation as a risk factor for cognitive decline and dementia

Archana Singh-Manoux¹,²*, Aurore Fayosse¹, Séverine Sabia¹,², Marianne Canonico¹, Martin Bobak², Alexis Elbaz¹, Mika Kivimäki², and Aline Dugravot¹

¹INSERM, U1018, Centre for Research in Epidemiology and Population Health, Université Paris-Saclay, Hôpital Paul Brousse, Bat 15/16, 16 Avenue Paul Vaillant Couturier, VILLEJUIF CEDEX, 94807, France; and ²Department of Epidemiology and Public Health, University College London, 1-19 Torrington Place, London WC1E 6BT, UK

Received 24 November 2016; revised 8 March 2017; editorial decision 30 March 2017; accepted 24 April 2017; online publish-ahead-of-print 29 April 2017

See page 2619 for the editorial comment on this article (doi: 10.1093/eurheartj/ehx320)

Aims
To assess whether AF is a risk factor for cognitive dysfunction we used prospective data on AF, repeat cognitive scores, and dementia incidence in adults followed over 45 to 85 years.

Methods and results
Data are drawn from the Whitehall II study, N = 10 308 at study recruitment in 1985. A battery of cognitive tests was administered four times (1997–2013) to 7428 participants (414 cases of AF), aged 45–69 years in 1997. Compared with AF-free participants, those with longer exposure to AF (5, 10, or 15 years) experienced faster cognitive decline after adjustment for sociodemographic, behavioural, and chronic diseases (P for trend = 0.01). Incident stroke or coronary heart disease individually did not explain the excess cognitive decline; however, this relationship was impacted when considering them together (P for trend 0.09). Analysis of incident dementia (N = 274/9302 without AF; N = 50/912 with AF) showed AF was associated with higher risk of dementia in Cox regression adjusted for sociodemographic factors, health behaviours and chronic diseases [hazard ratio (HR): 1.87; 95% confidence interval (CI): 1.37, 2.55]. Multistate models showed AF to increase risk of dementia in those free of stroke (HR: 1.67; 95% CI: 1.17, 2.38) but not those free of stroke and coronary heart disease (HR: 1.29; 95% CI: 0.74, 2.24) over the follow-up.

Conclusion
In adults aged 45–85 years AF is associated with accelerated cognitive decline and higher risk of dementia even at ages when AF incidence is low. At least in part, this was explained by incident cardiovascular disease in patients with AF.

Keywords
Atrial fibrillation • Cognitive decline • Dementia • Ageing

Introduction
The incidence of atrial fibrillation (AF), a type of cardiac arrhythmia which produces rapid and irregular heartbeat, rises steeply with age,⁴ and has major health consequences due to increased likelihood of thrombo-embolic complications and heart failure. The risk of stroke is increased as much as five-fold in patients with AF.⁵ Stroke is a risk factor for dementia,⁴ and there is consistent evidence that AF increases the risk of dementia, particularly in stroke patients.⁵ A recent meta-analysis reported associations of AF with cognitive impairment and dementia in those without stroke, although the associations were weaker than in stroke patients.⁶ Much of the evidence on AF and cognitive impairment, including studies in the recent systematic reviews,⁴,⁶ comes from data on the elderly among whom both conditions are more common, and their association might simply reflect manifestations of underlying systemic vascular disease. Disentangling the direction of association in studies on the elderly is complicated as bidirectional effects are common. For example, in older adults dementia is a risk factor for stroke and vice-versa.⁷,⁸ As the pathophysiological processes underlying

* Corresponding author. Tel: +33 (0) 7 74 74 10. Email: Archana.Singh-Manoux@inserm.fr
© The Author 2017. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
dementia unfold over a very long period prior to clinical onset, further evidence of the importance of AF for cognitive decline and dementia needs to examine whether AF at younger ages increases risk of accelerated cognitive decline and dementia.

To address some of these complexities, we sought to examine associations of incident AF with subsequent cognitive decline over the 45 to 85 year age span. Our aim was to determine the potential dose-response association of duration of exposure to AF on cognitive decline, and whether stroke and coronary heart disease (CHD) subsequent to AF mediated this association. We also examined whether AF increased dementia risk, and the extent to which it was mediated by stroke and CHD.

Methods

Study population
The Whitehall II study is an ongoing cohort study of persons originally employed by the British civil service. A total of 10,308 persons (33% women), aged 35–55 years, were recruited to the study over the years 1985–1988. All participants responded to a comprehensive questionnaire and underwent a uniform, structured clinical evaluation, consisting of measures of anthropometry, cardiovascular and metabolic risk factors and disease. Since the baseline medical examination, follow-up examinations have taken place approximately every 5 years. Participant consent and research ethics approvals (University College London (UCL) ethics committee) are renewed at each contact; the latest approval was by the Joint UCL/UCLH Committee on the Ethics of Human Research (Committee Alpha), reference number 85/0938.

Assessment of AF
Two sources were used: a twelve-lead resting ECG (Mingorec, Siemens Healthcare, Erlangen, Germany) at all 6 waves of data collection between 1985 and 2013, and interpreted for the presence of AF/flutter at the University of Glasgow (Prof. Macfarlane). Coding was carried out independently in duplicate by trained technicians; Minnesota codes 83x were used to identify cases of AF. The second source was the national hospital episode statistics (HES) database on hospital day cases and inpatients, using ICD9: 427.3 and ICD10: I48. The National Health Service (NHS) in the United Kingdom provides most of the health care, and record linkage is based on encrypted values of the NHS number, unique for each person.

Cognitive function
The cognitive test battery was introduced to the study in 1997 and data are available at four assessments until 2013. The tests, described below, provide a comprehensive assessment of cognitive function and are appropriate for this population composed of individuals younger than in most studies on cognitive ageing.

- Memory was assessed using a 20-word free recall test. Participants were presented a list of one or two syllable words at two second intervals and were then asked to recall in writing as many of the words in any order with two minutes to do so.
- Reasoning, assessed via the Alice Heim 4-I test which is composed of a series of 65 verbal and mathematical reasoning items of increasing difficulty. It tests inductive reasoning, measuring the ability to identify patterns and infer principles and rules. Participants had 10 minutes to do this section.
- Verbal fluency, measures of phonemic and semantic fluency were used. Participants were asked to recall in writing as many words beginning with ‘s’ (phonemic fluency) and as many animal names (semantic fluency) as they could. One minute was allowed for each test and the scores combined for the analysis.

A global cognitive score was created using all tests by first standardizing the raw scores to z-scores (mean = 0; standard deviation (SD) = 1) and then averaging and standardizing them.

Dementia
We used comprehensive tracing of electronic health records using three databases: HES, Mental Health Services Data Set (MHSDS) and the mortality register. Record linkage until 31st of March 2015, using ICD-10 codes F00, F01, F02, F03, F05.1, G30, G31.0, G31.1, and G31.8 identified cases of dementia. MHSDS is a national database which contains information for persons in contact with mental health services in hospitals, outpatient clinics, and the community. Mortality data were drawn from the British national mortality register. The validity of dementia ascertainment in our study is supported by findings on changes in the global cognitive score, showing accelerated decline in global cognitive score in the 8–10 years before dementia diagnosis (Supplementary material online, Figure S1). This is in agreement with previous studies that used a ‘gold-standard’ dementia ascertainment procedure.

Covariates
Socio-demographic measures included age, sex, ethnicity (white, non-white), and education (lower secondary school or less, higher secondary school (usually achieved at age 18), and university or higher degree). Analyses were also adjusted for health behaviours assessed by questionnaire, including smoking (current-, ex-, never-smoker); alcohol consumption (units of alcohol consumed in a week; no/occasional alcohol consumption, moderate alcohol consumption (1–14 (21) units/week in women (men), and heavy alcohol consumption (≥14 (21) units in women (men)); physical activity categorized as active (≥2.5 h/week of moderate physical activity or ≥1 h/week of vigorous physical activity), inactive (<1 h/week of moderate and vigorous activity), and intermediate level of activity for all others; and dietary behaviour self-reported frequency of fruit and vegetable consumption (<once a day, once a day, >once a day).

Chronic diseases included were hypertension (systolic/diastolic 140/90 mmHg or antihypertensive medication), prevalent diabetes mellitus (fasting glucose ≥ 7.0 mmol/L, a 2-h post-load glucose ≥ 11.1 mmol/L, doctor-diagnosed diabetes, diabetes medication), heart failure (ICD codes: I50), coronary heart disease (CHD, ICD codes: I20–I25), stroke (ICD codes: I60–I64), and self-reported use of medication for cardiovascular disease.

Statistical analysis
We examined associations between AF and participant characteristics in 1997–1999. Flow chart of persons included in the analyses described below is shown in Supplementary material online, Figure S2.

Analysis of cognitive decline
Mixed-effects models, with AF duration as a time varying covariate was used to estimate differences in cognitive decline between those without AF to those with AF exposure for 5, 10, and 15 years. The basic model (Model 1) contained time (here age, centred at 65 years), time squared, years since incident AF (0 = no AF, in years for those with AF), sex, ethnicity, education, and year of birth. Subsequent analyses (Model 2) were adjusted for health behaviours and chronic diseases in 1997–1999. Further analyses examined the mediating roles of stroke (Model 3), CHD (Model 4), and both stroke and CHD (Model 5) by including them as time varying covariates (1997 to 2013) in the analysis. The
model yielded mean effects for AF duration; subsequently an interaction term with age and age$^2$ was used to assess whether these effects varied as a function of age.

### Analysis of incident dementia

We first used Cox regression to analyse the association of AF with incidence of dementia. Participants were followed from 1985 until the record of dementia, death, or March 31st 2015, whichever came first. Age was the time scale and analyses adjusted for sex, ethnicity, and education (Model 1) and then for health behaviours and chronic diseases at baseline (Model 2).

In subsequent analyses, we examined the mediating role of stroke and CHD over the follow-up in the association between AF and incidence of dementia. These analyses were carried out using multistate models with a Weibull distribution. These models are an extension of competing risks survival analysis, allowing simultaneous estimation of the risk associated with AF in a) the incidence of stroke, b) the risk of dementia in those with stroke, and c) the risk of dementia in those free of stroke. Age was used as the timescale, and models were adjusted for sociodemographic factors, health behaviours, and chronic diseases at baseline. We repeated the analyses replacing stroke with CHD and then with CVD (stroke and CHD). These analyses were undertaken using R (SmoothHazard); all other analyses used Stata version 14. A two-sided $P$-value $< 0.05$ was considered statistically significant.

### Results

#### Analysis of cognitive decline

A total of 7428 participants were included in the analysis, characteristics in 1997–1999 presented in Table 1. A total of 43% of participants had data at all four assessments, 29% at three, 15% at two and 13% at only one assessment; a total of 414 cases of AF were used in the analysis.

The age range of participants at the beginning and end of follow-up was 45–69 years and 61–83 years; mean follow-up was 14.7 years and annual decline in global cognitive function was -0.050 SD (-0.054, -0.046). Excess cognitive decline, averaged across all age-groups, in analysis adjusted for all confounders (Model 2) was greater in those with AF for longer, $P < 0.01$ (Table 2 and Figure 1). Incident stroke (Model 3), or CHD (Model 4) over the follow-up did not explain the excess decline. However, when both stroke and CHD (Model 5) were taken into account, the estimate for excess cognitive decline in those with AF was no longer statistically significant. The interaction term to test whether the effect of AF duration on cognitive decline changed with age did not suggest differences ($P > 0.05$), despite stronger associations in the youngest and oldest participants (Table 2). Furthermore, consideration of the incidence of stroke and CHD (model 5) attenuated associations in all but the youngest group (15 years difference in decline $= -0.27$; 95% CI: -0.51, -0.03).

Supplementary material online, Tables S1 and S2 and Figure S3 show these results separately for the tests of memory, reasoning, and fluency; there were no associations with memory, even in the minimally adjusted model (Supplementary material online, Table S1).

#### Analysis of dementia

Of a total of 10,214 persons, followed over a mean 26.6 years, there were 912 cases of incident AF and 324 cases of dementia; 73% of the latter recorded in the last 5 years of follow-up. The mean (SD) age at incident AF and dementia diagnosis was 68.5 (7.7) and 74.9 (5.4) years, respectively. Table 3 shows that in analysis adjusted for all confounders (Model 2), those with AF had 87% excess risk (95% CI: 1.37, 2.55) of dementia. The association was somewhat stronger, albeit not statistically significant, in those with incident AF before 70 years (Table 3).

In multistate models, AF was associated with a 6.22 times increased risk of stroke (95% CI: 4.74, 8.16) and its association with dementia was not fully explained by stroke as demonstrated by the increased risk of dementia in those free of stroke (HR = 1.67; 95% CI: 1.17, 2.38), Figure 2A. Further analysis showed AF to increase risk of CHD (HR = 5.29; 95% CI: 4.50, 6.22; Figure 2B) and CVD (HR = 5.74; 95% CI: 4.95, 6.65; Figure 2C). The analysis of CVD (Figure 2C) shows that the association between AF and dementia was present in those with CVD (HR = 1.79; 95% CI: 1.04, 3.08) but not in those free of CVD (HR = 1.29; 95% CI: 0.74, 2.24).

### Discussion

Our study of cognitive decline over 15 years in adults aged 45–69 years at the start of follow-up shows greater cognitive decline in those with longer exposure to AF. Stroke occurring after the onset on AF did not explain this excess decline but when both stroke and CHD over the follow-up were taken into account the association between duration of exposure to AF and cognitive decline was no longer statistically significant. This finding was replicated in analysis of dementia where stroke explained only part of the association of AF.
## Table 2  Estimates of decline in the global cognitive score over 15 years in those with atrial fibrillation (AF) compared with those without AF

| Covariates at baseline | Stroke/CHD over the follow-up |
|------------------------|-------------------------------|
|                       | Model 1 | Model 1 + all covariates | Model 3 | Model 4 | Model 5 |
|                       | Beta (95% CI) | Beta (95% CI) | Beta (95% CI) | Beta (95% CI) | Beta (95% CI) |
| NO AF                  | Ref.    | Ref.                  | Ref.               | Ref.                | Ref.              |
| additional decline     | -0.03 (-0.09, -0.02)* | -0.05 (-0.09, -0.01)* | -0.04 (-0.08, -0.01)* | -0.04 (-0.08, -0.002)* | -0.03 (-0.07, 0.005) |
| when AF for 5 years    |         |                      |                   |                    |                   |
| additional decline     | -0.11 (-0.18, -0.03)* | -0.10 (-0.17, -0.02)* | -0.09 (-0.16, -0.01)* | -0.08 (-0.15, -0.004)* | -0.07 (-0.14, 0.01) |
| when AF for 10 years   |         |                      |                   |                    |                   |
| additional decline     | -0.16 (-0.27, -0.05)* | -0.15 (-0.26, -0.04)* | -0.13 (-0.24, -0.02)* | -0.12 (-0.23, -0.01)* | -0.10 (-0.21, 0.01) |
| when AF for 15 years   |         |                      |                   |                    |                   |
| \( P \) for trend      | 0.005   | 0.01                 | 0.02             | 0.04               | 0.09              |

15 year Cognitive Decline as a function of age

**CURRENT AGE**

| NO AF                  | Ref.    | Ref.                  | Ref.               | Ref.                | Ref.              |
|                       |         |                      |                   |                    |                   |
| 60 years              | -0.43 (-0.49, -0.37)* | -0.30 (-0.54, -0.06)* | -0.27 (-0.51, -0.04)* | -0.29 (-0.53, -0.06)* | -0.27 (-0.51, -0.03)* |
| additional decline    | -0.31 (-0.56, -0.07)* | -0.16 (-0.32, -0.01)* | -0.14 (-0.29, 0.01) | -0.17 (-0.32, -0.02)* | -0.14 (-0.30, 0.01) |
| when AF at 45 years   |         |                      |                   |                    |                   |
| 65 years              | -0.53 (-0.57, -0.49)* | -0.10 (-0.23, 0.02)  | -0.08 (-0.21, 0.04) | -0.10 (-0.22, 0.03) | -0.07 (-0.20, 0.05) |
| additional decline    | -0.18 (-0.33, -0.03)* | -0.02 (-0.24, 0.01)  |                   |                    |                   |
| when AF at 50 years   |         |                      |                   |                    |                   |
| 70 years              | -0.63 (-0.66, -0.59)* | -0.12 (-0.24, -0.01) |                   |                    |                   |
| additional decline    | -0.03 (-0.24, -0.01)  | -0.03 (-0.24, -0.01) |                   |                    |                   |
| when AF at 55 years   |         |                      |                   |                    |                   |
| 75 years              | -0.73 (-0.77, -0.68)* | -0.14 (-0.24, 0.001) | -0.10 (-0.22, 0.01) | -0.08 (-0.20, 0.04) | -0.06 (-0.18, 0.06) |
| additional decline    | -0.05 (-0.25, -0.01)  | -0.08 (-0.20, 0.04)  | -0.06 (-0.18, 0.06) |                   |                   |
| when AF at 60 years   |         |                      |                   |                    |                   |
| 80 years              | -0.83 (-0.89, -0.76)* | -0.20 (-0.38, -0.02)* | -0.12 (-0.31, 0.06) | -0.11 (-0.30, 0.08) |                   |
| additional decline    | -0.02 (-0.10, -0.04)  | -0.02 (-0.10, -0.04) | -0.11 (-0.30, 0.08) |                   |                   |
| when AF at 65 years   |         |                      |                   |                    |                   |
| 85 years              | -0.93 (-1.02, -0.83)* | -0.36 (-0.71, -0.01)* | -0.38 (-0.73, -0.03)* | -0.22 (-0.58, 0.14) | -0.21 (-0.57, 0.15) |
| additional decline    | -0.38 (-0.73, -0.03)* | -0.36 (-0.71, -0.01)* | -0.38 (-0.73, -0.03)* | -0.22 (-0.58, 0.14) | -0.21 (-0.57, 0.15) |
| when AF at 70 years   |         |                      |                   |                    |                   |
| Interaction between   | 0.16     | 0.14                 | 0.17             | 0.22               | 0.23              |
| AF duration and age, \( P \) |          |                     |                  |                    |                   |

Participants aged 45–69 years in 1997–1999 were followed until 2012–2013, mean follow-up 14.7 years. Estimates are for decline over 15 years.

Total \( N = 7428 \), atrial fibrillation, \( N = 414 \) * \( P < 0.05 \); CHD, coronary heart disease; CVD, cardiovascular disease (Stroke or CHD).

Model 1: Analysis uses age as the time-scale, adjusted for sex, education, and ethnicity.

Model 2: Model 1 + alcohol consumption, smoking, physical activity, diet, diabetes, hypertension, heart failure, CVD (stroke or CHD) and CVD medication at baseline (1997–1999).

Model 3: Model 2 + time-dependent Stroke (1997–2013), \( N = 109 \).

Model 4: Model 2 + time-dependent CHD (1997–2013), \( N = 1120 \).

Model 5: Model 2 + time-dependent CVD (1997–2013), \( N = 1182 \).
with dementia. Importantly, these findings relate to incident AF in relatively young adults as more than two thirds of AF cases in our analysis occurred before 75 years of age.

AF is a common disorder in the elderly,\(^17\) its prevalence increases with age, doubling every decade of life after the age of 50 years to reach 10–20% after the age of 80 years. As the prevalence of dementia also increases with age, its association with AF has sometimes been attributed to common age-related mechanisms. However, increasing evidence of associations with cognitive decline suggests that AF may indeed be a risk factor for cognitive dysfunction.\(^18\) To the best of our knowledge, few studies have been able to use serial cognitive testing, starting in mid-life to assess the impact of AF. We show that even in adults aged 60 years, those with incident AF at age 50 and 55 years had accelerated cognitive decline.

The effect of duration of AF has been examined in relation to dementia where the associations appear to be stronger in those with younger age of AF onset.\(^19\)–\(^21\) Stronger effects associated with longer duration of AF have also been seen for pre-stroke cognitive impairment,\(^8\) and total brain and grey matter volume.\(^22\) AF is associated with cerebral hypoperfusion and is a known cause of embolic stroke, from thrombus originating in the atrial appendage. It is possible that longer duration of exposure allows a greater time window for

### Table 3  Association of atrial fibrillation (AF) with incidence of dementia

| Atrial fibrillation | N total | N cases | Model 1 HR (95% CI) | Model 2 HR (95% CI) |
|---------------------|---------|---------|---------------------|---------------------|
| No                  | 9302    | 274     | 1.00                | 1.00                |
| Yes                 | 912     | 50      | 1.93 (1.42, 2.63)   | 1.87 (1.37, 2.55)   |
| Analysis stratified by age of onset of AF | | | | |
| No                  | 9302    | 274     | 1.00                | 1.00                |
| AF before age 70    | 500     | 21      | 2.15 (1.37, 3.37)   | 2.11 (1.35, 3.32)   |
| AF after age 70     | 412     | 29      | 1.79 (1.20, 2.65)   | 1.72 (1.15, 2.55)   |
| P for interaction   |         |         | 0.50                | 0.45                |

Model 1: Analysis adjusted for age, sex, education, and ethnicity.
Model 2: Model 1 + alcohol consumption, smoking, physical activity, diet, diabetes, hypertension, heart failure, CVD (stroke or CHD), and CVD medication at baseline.

![Figure 1](image-url)  
Decline in the global cognitive score as a function of atrial fibrillation (AF). *Analysis uses age as the time scale, adjusted for sex, education, and ethnicity. P-values represent the test for trend for greater effects on cognitive decline in longer exposure to AF.
damage from chronic hypoperfusion and development of emboli and cardiac failure. AF alters atrial size, substrate, and cardiac function, which develop very early after diagnosis, and increases the risk of macro- and micro-cerebral ischaemic events.

The association of AF with cognitive impairment, cognitive decline, hippocampal atrophy, and dementia, appears to be independent of stroke history. We extended these findings by considering stroke occurring after AF to show that it does not explain associations with cognitive decline and dementia. A third of those with AF have silent infarction and cerebrovascular thrombo-embolism together with global brain hypoperfusion due to impaired cardiac haemodynamics, may account for the increased risk of developing dementia in AF patients. Our findings highlight the importance of CVD in the association of AF with cognitive outcomes. The association of AF with dementia in our study is similar to that in previous studies, particularly studies that examined AF onset at younger ages. It remains unclear whether it affects risk of all types of dementia; one study found evidence of stronger associations with Alzheimer’s disease, another showed the type of dementia not to matter, while MRI data associations with lower total grey matter but not neurodegenerative changes characteristic of Alzheimer’s disease.

The main strengths of our study include the large sample size, consideration of both cognitive decline and dementia, modelling of time lived with AF, and explicit analysis of the role played by stroke and CHD after AF onset—important consideration given the strong association of AF with these conditions. Our results on the interaction effects with age suggest that the effect of AF on cognitive decline is not confined to older ages. We present results using the global cognitive score, allowing replication across studies in the future. We have previously shown the risk factor-CVD associations in our study to be similar to that in a general population study, suggesting that the present findings are generalizable.

Limitations of the study include the method of dementia ascertainment, which has high specificity but is unlikely to be sensitive. The fact that dementia tracing was available on all participants in the study allows the study results to be free from attrition and selection biases that are common in studies on older adults. Furthermore, the AF-CVD association in our study was similar to that in other studies, suggesting that case definitions for both conditions are valid. We were not able to distinguish paroxysmal from persistent AF, in previous studies the latter was more strongly associated with silent cerebral ischaemia and worse cognitive function, and higher incidence of adverse cardiovascular outcomes even in patients treated by anti-coagulated therapy. We were also limited by the smaller number of patients with AF, particularly in subgroup analysis (e.g. those with incident CVD) that resulted in broad confidence limits.

In sum, AF is the most common arrhythmia and its most well established consequence is stroke. With ageing of populations its impact on cognitive impairment and dementia has become increasingly important and understanding this association has relevance for the development of preventive and therapeutic strategies. AF can be treated with antiarrhythmic medication, cardioversion, or catheter ablation. Furthermore, thrombo-prophylaxis with oral anticoagulation is effective in reducing stroke risk, whether the same is true for dementia is unknown. The present longitudinal study shows that early onset AF and its duration matters for cognitive decline and dementia and highlight the importance of effectively treating cardiovascular disease in AF patients. In those with early age of AF onset, a longer exposure period might lead to changes that produce greater neuronal injury and loss, possibly due to the interaction of degenerative and vascular changes.

**Supplementary material**

Supplementary material is available at European Heart Journal online.

**Funding**

The Whitehall II study is supported by grants from the US National Institute on Aging (R01AG013196; R01AG034454); the UK Medical Research Council (MR/K013351/1). M.K. is supported by the MRC and NordForsk. MRC (MR/K013351/1) via a prepayment account with UCL.
Conflict of interest: none declared.

References

1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendrikx J, Hendriks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Ageval S, Camm J, Baron Esquivias G, Budts W, Careny S, Casselman F, Costa A, De Caterina R, Deffereos S, Dobbrev D, Ferro JM, Filipatos G, Fitzsimons D, Gorenèk B, Guenoun M, Hohnloser SH, Kohl P, Lip GY, Manolis A, McMurray J, Nieuwlaat R, Palatini P, Rasmussen R, Ruschitzka F, Saleveia I, Sharma S, Suwalski P, Tamargo J, Taylor CJ, Van Gelder IC, Voors AA, Windenius S, Zannad F, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893–2962.

2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983–988.

3. Leys D, Heron H, Mackowiak-Cordoliani MA, Pasquier F. Poststroke dementia. Lancet Neurol 2005;4:752–759.

4. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol 2009;8:1006–1018.

5. Kwap CS, Loke YK, Hale R, Potter JF, Myint PK. Atrial fibrillation and incidence of dementia: a systematic review and meta-analysis. Neurology 2011;76:914–922.

6. Kalantar A, Stem TA, Mansour M, Ruskin JN. Cognitive impairment associated with atrial fibrillation: a meta-analysis. Ann Intern Med 2013;158:338–346.

7. Imfeld P, Bodmer M, Schuerch M, Jick SS, Meier CR. Risk of incident stroke in patients with Alzheimer disease or vascular dementia. Neurology 2013;81:910–919.

8. Horstmann S, Rizos T, Rauch G, Fuchs M, Arden C, Veltkamp R. Atrial fibrillation and pre-stroke cognitive impairment in stroke. J Neurol 2014;261:46–53.

9. Jack CR, Jr, Inzitari D, Pantoni L. Atrial fibrillation and cognition: epidemiological evidence and clinical implications. Heart Rhythm 2015;12:207–216.

10. Marmot MG, Smith GD, Stansfeld S, Matheson B, Rose G, cook R. Health inequalities among British civil servants: the Whitehall II study. Lancet 1991;337:1387–1393.

11. Prince NJ, Crowe RS, Blackburn H. The Minnesota Code Manual of Electrocardiographic Findings: Standards and Procedures for Measurement and Classification. Bristol, UK: John Wright; 1982.

12. Singh-Manoux A, Kivimäki M, Glymour MM, Berr C, Ebmeier KP, Ferrie JE, Deary IJ, Davey Smith G, Shipley MJ, Brunner EJ, Dugravot A. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004;110:1042–1046.

13. Heim AW, Ahrens WD, Kolecki J, Odersky S, Timmermann M, Bortz F, Trojanowski JQ. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12:207–216.

14. Hideki H, Loney M, Wells C, Tishelman C, Heindel W, Albrecht T, et al. Atrial fibrillation and cognitive decline: a longitudinal cohort study. Neurology 2013;81:119–125.

15. Amieva H, Le GM, Millet X, Orgogozo JM, Peres K, Barber-Gaute P, Jacqmin-Gadda H, Dartigues JF. Prodromal Alzheimer’s disease: successive emergence of the clinical symptoms. Ann Neurol 2008;64:492–498.

16. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. Hoboken, New Jersey: Wiley; 2004.

17. Sweetenby DM, Wang TJ, Leip EP, Larson MG, Levy D, Asirvatham SJ, Benjamin EJ. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004;110:1042–1046.

18. Thacker EL, McKnight B, Patsy BM, Longstreth WT, Jr, Sitman CM, Munich DL, Arnold AM, Fitzpatrick AL, Gottesman RF, Heckbert SR. Atrial fibrillation and cognitive decline: a longitudinal cohort study. Neurology 2013;81:119–125.

19. de Bruijn RF, Heeringa J, Wolters FJ, Franco OH, Stokroos B, Hofman A, Koudstaal PJ, Ikram MA. Association between atrial fibrillation and dementia in the general population. JAMA Neurol 2015;72:1288–1294.

20. Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 1997;28:316–321.

21. Jacobs V, Cutler MJ, Day JD, Bunch TJ. Atrial fibrillation and dementia. Trends Cardiovasc Med 2015;25:44–51.

22. Stefandottir H, Aarnan DO, Aspelund T, Sigurdsson S, Jensdottir MK, Hjaltason H, Launer LJ, Gudnason V. Atrial fibrillation is associated with reduced brain volume and cognitive function independent of cerebral infarcts. Stroke 2013;44:1020–1025.

23. Gaia F, Corsinovi L, Asselmia M, Raimondo C, Panelli M, Toso E, Bergamasco L, Boffano C, Valentini MC, Cersaniti S, Scaglione M. Prevalence of silent cerebral ischemia in paroxysmal and persistent atrial fibrillation and correlation with cognitive function. J Am Coll Cardiol 2013;62:1990–1997.

24. Chen LY, Lopez FL, Gottesman RF, Huxley RR, Agarwal SK, Loehr L, Mosley T, Alonso A. Atrial fibrillation and cognitive decline—the role of subclinical cerebral infarcts: the atherosclerosis risk in communities study. Stroke 2014;45:2568–2574.

25. Knecht S, Oelschlager C, Duning T, Lehmann H, Albers J, Stething C, Heindel W, Breithardt G, Berger K, Ringelstein EB, Kirchhof P, Wersching H. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J 2008;29:2125–2132.

26. Santangelo P, Di Balse L, Bai R, Mohanty S, Pamp A, Cereceda Brantes M, Horton R, Burkhart J, Lakireddy D, Reddy YMY, Castell M, Dello Russo A, Tondo C, Natale A. Atrial fibrillation and the risk of incident dementia: a meta-analysis. Heart Rhythm 2012;9:1761–1768.

27. Graaf-Radford J, Madhavan M, Vernuri P, Rabinstein AA, Cha RH, Mikels MM, Kantarci K, Lowe V, Senjem ML, Gunter JL, Knopman DS, Petersen RC, Jack CR, Jr, Roberts RO. Atrial fibrillation, cognitive impairment, and neuroimaging. Alzheimers Dement 2016;12:391–398.

28. Batty GD, Shipley M, Tabak A, Singh-Manoux A, Brunner EJ, Britton A, Kivimäki M. Generalizability of occupational cohort study findings. Epidemiology 2014;25:932–933.

29. Seno K, Lip GY, Lane DA, Buller HR, Kotecha D. Residual risk of stroke and death in anticoagulated patients according to the type of atrial fibrillation: the AMADEUS trial. Stroke 2015;46:2523–2528.

30. Poggesi A, Inzitari D, Piantoni L. Atrial fibrillation and cognition: epidemiological data and possible mechanisms. Stroke 2015;46:3316–3321.